Aclaris Therapeutics, Inc. ACRS 深 滬
已收盤 02-06 16:00:00 美东时间
3.57
+0.180
+5.31%
華盛通- 最 高3.65
- 今 開3.36
- 成交量 157.29万股
- 最 低 3.30
- 昨 收 3.39
- 總市值 3.87亿
- 52周最高 4.89
- 市盈率 靜 --
- 換手率 1.45%
- 52周最低 1.05
- 委 比 -17.92%
- 總股本 1.08亿
- 歷史最高 33.88
- 量 比 1.42
- 振 幅 10.32%
- 歷史最低 0.5902
- 每 手 1
- 風險率 0.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug
Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting hair regrowth, outperforming Pfizer's Litfulo in a severe hair loss mouse model.
01-28 02:12
Aclaris Therapeutics’ ATI-2138 Shows Superior Hair Regrowth in Severe Alopecia Areata Preclinical Study
Aclaris Therapeutics’ ATI-2138 Shows Superior Hair Regrowth in Severe Alopecia Areata Preclinical Study Aclaris Therapeutics Inc. announced positive preclinical results for its novel ITK/JAK3 inhibitor, ATI-2138, in a murine model of severe alopecia areata. In the study, ATI-2138 demonstrated rapid,
01-27 23:01
美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and maintains $16 price target.
01-21 19:28
美股牛股 | Corvus制药飙升166%，皮炎新药1期临床试验结果积极；RAPT大涨逾60%
Corvus制药飙升166%，皮炎新药临床试验结果积极；RAPT大涨逾60%，获葛兰素史克以22亿美元溢价收购；黄金资源大涨24%，财报强劲叠加金银价齐创新高>>
01-21 18:51
Aclaris Therapeutics Expands Inflammation and Immunology Pipeline Strategy
An update from Aclaris Therapeutics ( ($ACRS) ) is now available. On January 12...
01-12 20:40
Aclaris advances ATI-052 after positive Phase 1a results
Aclaris Therapeutics ( ($ACRS) ) just unveiled an announcement. On January 6, 2...
01-06 20:50
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
Aclaris Therapeutics announced positive interim results from the Phase 1a SAD/MAD trial of ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, showing strong safety, tolerability, and pharmacokinetic profiles. The drug demonstrated robust target engagement and sustained inhibition of inflammatory markers, supporting potential every three-month dosing. Aclaris plans to initiate Phase 1b proof-of-concept trials in atopic dermatitis (AD) and asthma in...
01-06 11:59
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has been added to the Nasdaq Biotechnology Index (NBI) as of December 19, 2025. The NBI tracks biotech and pharmaceutical companies listed on Nasdaq, requiring them to meet criteria like market cap, trading volume, and public seasoning. Aclaris, a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, joins the index after meeting these requirements. The NBI is recalculated an...
2025-12-19 21:01
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Aclaris Therapeutics announced that its CEO, Dr. Neal Walker, and other senior leaders will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City on December 2, 2025, at 11:00 AM EST. A live and archived webcast will be available on the company's website for at least 30 days. Aclaris specializes in developing novel treatments for immuno-inflammatory diseases. For more information, visit www.aclaris...
2025-11-25 13:00
